A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2019
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2019 Planned End Date changed from 1 Nov 2019 to 21 Aug 2020.
- 21 Feb 2019 Planned primary completion date changed from 1 Nov 2019 to 21 Aug 2020.
- 03 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.